BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32461259)

  • 1. Rare ovarian tumors: an update on diagnosis and treatment.
    Debuquoy C; Romeo C; Vanacker H; Ray-Coquard I
    Int J Gynecol Cancer; 2020 Jun; 30(6):879-887. PubMed ID: 32461259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Preinvasive lesions in gynaecology -  ovary].
    Feranec R; Mouková L
    Klin Onkol; 2013; 26 Suppl():S54-5. PubMed ID: 24325167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
    Ramalingam P
    Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors.
    McCluggage WG; Young RH
    Semin Diagn Pathol; 2005 Feb; 22(1):3-32. PubMed ID: 16512597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detailed overview on rare malignant ovarian tumors.
    Aust S; Eberst L; Tredan O; Rousset-Jablonski C; Treilleux I; Méeus P; Chopin N; Beurrier F; Charreton A; Véronique D; Hallouz A; Coulon A; Ricoeur A; Mastier C; Bouhamama A; Racadot S; Devouassoux-Shisheboran M; Haddad V; Ray-Coquard I
    Bull Cancer; 2020 Mar; 107(3):385-390. PubMed ID: 32115180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Rare ovarian tumours: therapeutic strategies in 2010, national website observatory for rare ovarian cancers and delineation of referent centers in France].
    Ray-Coquard I; Pautier P; Pujade-Lauraine E; Méeus P; Morice P; Treilleux I; Duvillard P; Alexandre J; Lhommé C; Selle F; Guastalla J
    Bull Cancer; 2010 Jan; 97(1):123-35. PubMed ID: 20007069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference.
    Jang JYA; Yanaihara N; Pujade-Lauraine E; Mikami Y; Oda K; Bookman M; Ledermann J; Shimada M; Kiyokawa T; Kim BG; Matsumura N; Kaku T; Kuroda T; Nagayoshi Y; Kawabata A; Iida Y; Kim JW; Quinn M; Okamoto A
    J Gynecol Oncol; 2017 Jul; 28(4):e54. PubMed ID: 28541641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
    Morgan RJ; Armstrong DK; Alvarez RD; Bakkum-Gamez JN; Behbakht K; Chen LM; Copeland L; Crispens MA; DeRosa M; Dorigo O; Gershenson DM; Gray HJ; Hakam A; Havrilesky LJ; Johnston C; Lele S; Martin L; Matulonis UA; O'Malley DM; Penson RT; Percac-Lima S; Pineda M; Plaxe SC; Powell MA; Ratner E; Remmenga SW; Rose PG; Sabbatini P; Santoso JT; Werner TL; Burns J; Hughes M
    J Natl Compr Canc Netw; 2016 Sep; 14(9):1134-63. PubMed ID: 27587625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian mucinous tumor with malignant mural nodules: dedifferentiation or collision?
    Desouki MM; Khabele D; Crispens MA; Fadare O
    Int J Gynecol Pathol; 2015 Jan; 34(1):19-24. PubMed ID: 25473748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer].
    Rousset-Jablonski C; Selle F; Adda-Herzog E; Planchamp F; Selleret L; Pomel C; Chabbert-Buffet N; Daraï E; Pautier P; Trémollières F; Guyon F; Rouzier R; Laurence V; Chopin N; Faure-Conter C; Bentivegna E; Vacher-Lavenu MC; Lhomme C; Floquet A; Treilleux I; Lecuru F; Gouy S; Kalbacher E; Genestie C; de la Motte Rouge T; Ferron G; Devouassoux-Shisheboran M; Kurtz JE; Namer M; Joly F; Pujade-Lauraine E; Grynberg M; Querleu D; Morice P; Gompel A; Ray-Coquard I
    Bull Cancer; 2018 Mar; 105(3):299-314. PubMed ID: 29397916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histotype classification of ovarian carcinoma: A comparison of approaches.
    Peres LC; Cushing-Haugen KL; Anglesio M; Wicklund K; Bentley R; Berchuck A; Kelemen LE; Nazeran TM; Gilks CB; Harris HR; Huntsman DG; Schildkraut JM; Rossing MA; Köbel M; Doherty JA
    Gynecol Oncol; 2018 Oct; 151(1):53-60. PubMed ID: 30121132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant ascites occurs most often in patients with high-grade serous papillary ovarian cancer at initial diagnosis: a retrospective analysis of 191 women treated at Bayreuth Hospital, 2006-2015.
    Krugmann J; Schwarz CL; Melcher B; Sterlacci W; Ozalinskaite A; Lermann J; Agaimy A; Vieth M
    Arch Gynecol Obstet; 2019 Feb; 299(2):515-523. PubMed ID: 30415435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histologic subtypes of ovarian carcinoma: an overview.
    Soslow RA
    Int J Gynecol Pathol; 2008 Apr; 27(2):161-74. PubMed ID: 18317227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clear cell carcinoma of the ovary: a review of the literature.
    del Carmen MG; Birrer M; Schorge JO
    Gynecol Oncol; 2012 Sep; 126(3):481-90. PubMed ID: 22525820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updates and emerging therapies for rare epithelial ovarian cancers: one size no longer fits all.
    Groen RS; Gershenson DM; Fader AN
    Gynecol Oncol; 2015 Feb; 136(2):373-83. PubMed ID: 25481800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival rates for international federation of gynecology and obstetrics stage III ovarian carcinoma by cell type: a study of 262 unselected patients with uniform pathologic review.
    Seidman JD; Yemelyanova A; Cosin JA; Smith A; Kurman RJ
    Int J Gynecol Cancer; 2012 Mar; 22(3):367-71. PubMed ID: 22237384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
    Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG
    Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathology of borderline and invasive cancers.
    Prat J
    Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():15-30. PubMed ID: 28277307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.